Alberta Regulator Dismisses Curaleaf's Bid to Halt Aurora's ATM Program
ACB sits 52% above its 52-week low of $2.56.
Summary
Aurora won a regulatory ruling as the Alberta Securities Commission dismissed Curaleaf's application to halt its ATM program; the company confirmed the ATM has not been used since August 18, 2026, during the hostile bid.
Key Events · Legal and Risk Events · ACB
-
Regulator Dismisses Curaleaf ATM Challenge
The Alberta Securities Commission dismissed Curaleaf's application to halt Aurora's at-the-market program, ruling the program compliant with securities laws.
-
ATM Unused During Hostile Bid
Aurora reaffirmed the last day it used the ATM was August 18, 2026, and that it has not been used during the hostile bid process.
-
Board Urges Rejection of Revised Bid
Aurora's board continues to unanimously recommend shareholders reject Curaleaf's revised hostile bid by taking no action and not tendering shares.
-
Prior Disclosure Context
On September 14, 2026, Aurora responded to Curaleaf's application to halt the ATM, calling it a distraction from the inadequate bid; this filing reports the outcome.
Analysis · ACB · Life Sciences
A legal obstacle Curaleaf raised during its hostile takeover bid has been removed: the Alberta Securities Commission rejected its application to stop Aurora's at-the-market program. Aurora also confirmed it last used the ATM on August 18, 2026 and has not drawn on it since the bid began, which blunts Curaleaf's argument that the program was being used to entrench the board. With financing flexibility intact, the board continues to urge shareholders to reject the revised bid and pursue strategic alternatives.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $3.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $255.1M. The 52-week trading range was $2.56 to $6.36. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.